Lung Cancer Genomic Screening Project for Individualized Medicine in Japan (LC-SCRUM-Japan): Prospective analyses of clinicopathological and molecular characteristics in small cell lung cancer harboring rare gene alterations including PI3K/AKT/mTOR pathway mutations (LC-SCRUM-Japan-SCLC)

Lung Cancer Genomic Screening Project for Individualized Medicine in Japan (LC-SCRUM-Japan): Prospective analyses of clinicopathological and molecular characteristics in small cell lung cancer harboring rare gene alterations including PI3K/AKT/mTOR pathway mutations (LC-SCRUM-Japan-SCLC) - LC-SCRUM-Japan-SCLC

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000018656

Enrollment

1000

Registered

2015-08-12

Start date

2015-07-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Histologically or cytologically confirmed small cell lung cancer 2.Chemotherapy is planned 3.ECOG performance status of 0 to 2 4.Adequate organ function (Correspond to the following values in laboratory tests performed within 14 days before registration) a.Neutrophil count >= 1,500/mm3 b.Hemoglobin >= 8.0g/dL c.Platelet count >= 75,000/mm3 d.AST,ALT: <= upper limits of normal (ULN)x2.5 (patients with liver metastasis; AST,ALT: <= ULNx5.0) e.Total bilirubin: <= ULNx1.5 5.No serious comorbidities (for example: interstitial pneumonia, or uncontrolled diabetes mellitus, heart disease or infection) 6.Life expectancy of at least 3 months 7.Samples suitable for genomic analysis 8.Intention to register clinical trials 9.Written informed consent

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
To clarify the clinicopathological and molecular feature in small cell lung cancer harboring PI3K/AKT/mTOR pathway mutations	—

Secondary

Measure	Time frame
To evaluate the frequencies and characteristics of any cancer-related gene alterations in small cell lung cancer using OCP (Cancer Panel)	—

Countries

Japan

Contacts

Public ContactKoichi Goto

National Cancer Center Hospital East Department of Thoracic Oncology

kgoto@east.ncc.go.jp04-7133-1111

Outcome results